Press Release Summary:
Without need for ethyl acetate or ether derived products, Parasep SF facilitates clean and efficient concentration of helminth ova and larvae as well as protozoal cysts and oocysts. Product's dual filter technology removes fecal debris and solubilizes fat content to prevent interference with resulting sediment. Providing clean sample with recovery of all parasite stages, Parasep also reduces operator risk and promotes safe disposal.
Original Press Release:
DiaSys Corporation Announces the Introduction of Parasep SF Solvent Free Parasite Concentrator
WATERBURY, Conn., Nov. 20 -- DiaSys Corporation (BULLETIN BOARD: DYXC) today announced the product introduction of Parasep SF, a solvent free fecal parasite concentrator that eliminates the need for ethyl acetate or ether derived products for the clean and efficient concentration of helminth ova and larvae and protozoal cysts and oocysts. The new dual filter technology removes the smaller fecal debris and solubilizes the fat content so that it does not interfere with the resulting sediment without the use of ether or ethyl acetate. The Parasep SF provides a safe, clean sample with excellent recovery of all parasite stages and removes the problems of operator risk and safe disposal. Parasep SF has been designed to fully integrate into the DiaSys Corporation FE-5 workstation that has now been modified by enlarging the viewable sample in its Optical Slide Assembly. This fully integrated system prevents the unauthorized use of other concentrators.
DiaSys Corporation launched the new product at the MEDICA trade show in Dusseldorf Germany, November 15-18, 2006.
"We are excited about the potential for Parasep SF. It will provide health and safety benefits for all product users. In the Andean countries where ether and ether-derived products are banned, Parasep SF will enable those countries to perform better testing for parasites. We look forward to expanding the Parasep SF product applications into areas that were previously unavailable to this technology" stated Gregory Witchel, Chief Executive Officer, DiaSys Corporation.
DiaSys Corporation designs, develops, manufactures and distributes proprietary medical laboratory equipment, consumables and infectious disease test-kits to healthcare & veterinary laboratories worldwide. Headquartered in Waterbury, Connecticut USA, the Company operates in Europe through its wholly owned subsidiary based in Wokingham, England and through distributors in South America.
Source: DiaSys Corporation
Chief Executive Officer
Web site: http://www.diasys.com/